HSBC Research continues to be optimistic about the mainland CDMO industry, recommending to buy Pharmaron and WUXI XDC

AASTOCKS
2025.10.15 02:34

HSBC Global Research report indicates that the United States recently passed the "Biosecurity Act," which prohibits federal agencies from procuring, renewing, or extending contracts related to "concerned biotechnology companies."

The bank believes that the relevant legislation may cause market volatility in the short term, but remains optimistic about the long-term growth of China's CDMO industry, as companies can manage risks by diversifying business regions, expanding non-U.S. clients, and avoiding direct contracts. The bank stated that the earnings visibility of industry leaders remains robust, and the legislation allows for a 5-year exemption period for signed contracts, which should have a limited impact on short-term operations.

In terms of stocks, the bank is more optimistic about Pharmaron (03759.HK) and WUXI XDC (02268.HK), both rated "Buy," with target prices of HKD 28.1 and HKD 90, respectively

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.